NFAT1 deficit and NFAT2 deficit attenuate EAE via different mechanisms

Area of Science:

• Immunology
• Neuroscience
• Molecular Biology

Background:

• Experimental autoimmune encephalomyelitis (EAE) is a T cell-mediated autoimmune disease modeling multiple sclerosis.
• Activation of the Nuclear Factor of Activated T cells (NFAT) transcription factor family is crucial in the central nervous system (CNS) during EAE pathogenesis.
• NFAT signaling in autoreactive T cells is implicated in the recognition of myelin antigens within the CNS.

Purpose of the Study:

• To investigate the essential role of NFAT transcription factors in the induction and progression of EAE.
• To determine the specific contributions of NFAT1 and NFAT2 isoforms in T cell-mediated autoimmune responses.
• To explore the potential of targeting NFAT signaling as a therapeutic strategy for multiple sclerosis.

Main Methods:

• Utilized genetically modified mice deficient in NFAT1 (NFATc2) and/or NFAT2 (NFATc1) to study EAE.
• Assessed disease severity and course in NFAT-deficient mouse models.
• Analyzed T cell populations (Th17, Th2) and cytokine profiles (IL-17, IL-4, IL-10) in NFAT-deficient mice.

Main Results:

• Combined deficiency of NFAT1 and NFAT2 completely protected mice from EAE induction.
• Single deficiency in either NFAT1 or NFAT2 ameliorated EAE, with NFAT2 ablation hindering the pro-inflammatory response.
• NFAT1 deficiency promoted an anti-inflammatory response characterized by IL-4 and IL-10 secretion from Th17 and Th2 cells, mediated by NFAT2.
• IL-4 and IL-10 were identified as key mediators of disease protection in NFAT1-deficient mice.

Conclusions:

• NFAT signaling is essential for EAE induction and disease progression.
• Selective blockade of NFAT1, rather than global NFAT inhibition, may offer a safe and effective immunomodulatory treatment for multiple sclerosis.
• Targeting NFAT1 could provide a long-term therapeutic approach for multiple sclerosis, potentially avoiding broad immunosuppressive side effects.